SG10201912763QA - Modified friedreich ataxia genes and vectors for gene therapy - Google Patents

Modified friedreich ataxia genes and vectors for gene therapy

Info

Publication number
SG10201912763QA
SG10201912763QA SG10201912763QA SG10201912763QA SG10201912763QA SG 10201912763Q A SG10201912763Q A SG 10201912763QA SG 10201912763Q A SG10201912763Q A SG 10201912763QA SG 10201912763Q A SG10201912763Q A SG 10201912763QA SG 10201912763Q A SG10201912763Q A SG 10201912763QA
Authority
SG
Singapore
Prior art keywords
vectors
gene therapy
friedreich ataxia
modified
ataxia genes
Prior art date
Application number
SG10201912763QA
Other languages
English (en)
Inventor
Richard J Samulski
Original Assignee
Bamboo Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bamboo Therapeutics Inc filed Critical Bamboo Therapeutics Inc
Publication of SG10201912763QA publication Critical patent/SG10201912763QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Physics & Mathematics (AREA)
SG10201912763QA 2015-11-05 2016-11-01 Modified friedreich ataxia genes and vectors for gene therapy SG10201912763QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562251288P 2015-11-05 2015-11-05
US201662411980P 2016-10-24 2016-10-24

Publications (1)

Publication Number Publication Date
SG10201912763QA true SG10201912763QA (en) 2020-02-27

Family

ID=57288476

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201912763QA SG10201912763QA (en) 2015-11-05 2016-11-01 Modified friedreich ataxia genes and vectors for gene therapy
SG11201802408RA SG11201802408RA (en) 2015-11-05 2016-11-01 Modified friedreich ataxia genes and vectors for gene therapy

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201802408RA SG11201802408RA (en) 2015-11-05 2016-11-01 Modified friedreich ataxia genes and vectors for gene therapy

Country Status (18)

Country Link
US (2) US10548947B2 (zh)
EP (1) EP3370778A1 (zh)
JP (2) JP6767483B2 (zh)
KR (2) KR102200642B1 (zh)
CN (1) CN108348621A (zh)
AU (2) AU2016347887B2 (zh)
BR (1) BR112018007453A2 (zh)
CA (1) CA2947584A1 (zh)
CO (1) CO2018004564A2 (zh)
HK (1) HK1250924A1 (zh)
IL (1) IL259141A (zh)
MX (1) MX2018005084A (zh)
PE (1) PE20181156A1 (zh)
PH (1) PH12018500964A1 (zh)
RU (2) RU2743792C2 (zh)
SG (2) SG10201912763QA (zh)
TW (2) TWI654301B (zh)
WO (1) WO2017077451A1 (zh)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016172659A1 (en) * 2015-04-24 2016-10-27 University Of Florida Research Foundation, Inc. Aav vector for treatment of friedreich's ataxia
GB201508026D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Capsid
ES2799515T3 (es) 2015-05-22 2020-12-18 Dmitry Dmitrievich Genkin ADN extracelular como una diana terapéutica en la neurodegeneración
BR112018007453A2 (pt) * 2015-11-05 2018-10-23 Bamboo Therapeutics Inc genes modificados de ataxia de friedreich e vetores para a terapia gênica
US12011488B2 (en) 2016-03-23 2024-06-18 The Regents Of The University Of California Methods of treating mitochondrial disorders
CN109476716A (zh) * 2016-03-23 2019-03-15 加利福尼亚大学董事会 治疗线粒体障碍的方法
CN109642996A (zh) 2016-09-21 2019-04-16 康普技术有限责任公司 适配器块组件
CA3042706A1 (en) 2016-11-09 2018-05-17 Intrexon Corporation Frataxin expression constructs
AU2018346102B2 (en) 2017-10-03 2023-05-11 Prevail Therapeutics, Inc. Gene therapies for lysosomal disorders
CN112553210A (zh) 2017-10-03 2021-03-26 普利维尔治疗公司 用于溶酶体障碍的基因疗法
WO2019070893A1 (en) * 2017-10-03 2019-04-11 Prevail Therapeutics, Inc. GENE THERAPIES FOR LYSOSOMAL DISORDERS
HUE062806T2 (hu) * 2017-10-17 2023-12-28 Fundacio Inst Dinvestigacio En Ciencies De La Salut Germans Trias I Pujol Vektorok Friedreich-ataxia kezelésére
KR20200122320A (ko) 2018-01-16 2020-10-27 씨엘에스 테라퓨틱스 리미티드 데옥시리보뉴클레아제 (dnase) 활성을 갖는 효소의 간 발현에 의한 질환의 치료
BR112020020266A2 (pt) 2018-04-03 2021-01-19 Stridebio, Inc. Vetores de vírus com evasão de anticorpos
CA3108289A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
CN113166240A (zh) * 2018-08-02 2021-07-23 达因疗法公司 肌肉靶向复合物及其用于治疗弗里德赖希共济失调的用途
KR20210049833A (ko) * 2018-08-10 2021-05-06 로직바이오 테라퓨틱스, 인크. Mma의 치료를 위한 비-붕괴적 유전자 요법
WO2020069461A1 (en) * 2018-09-28 2020-04-02 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
US20220054656A1 (en) * 2018-11-16 2022-02-24 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus for treating pompe disease
MX2021005997A (es) * 2018-11-21 2021-08-11 Vectores virales recombinantes y acidos nucleicos para producirlos.
CA3133453A1 (en) 2019-03-21 2020-09-24 Daniel Mccoy Recombinant adeno-associated virus vectors
MX2021011824A (es) * 2019-03-27 2021-12-10 Sigilon Therapeutics Inc Composiciones, dispositivos y metodos para la terapia del factor vii.
WO2020210713A1 (en) 2019-04-10 2020-10-15 Prevail Therapeutics, Inc. Gene therapies for lysosomal disorders
EP3989994A4 (en) * 2019-06-30 2023-08-09 John Fraser Wright RECOMBINANT AAV VECTORS WITH ALTERED IMMUNOGENICITY AND METHODS FOR THEIR PRODUCTION
US20220372512A1 (en) * 2019-07-04 2022-11-24 Children's Medical Research Institute Methods and aav vectors for in vivo transduction
WO2021011368A1 (en) * 2019-07-12 2021-01-21 Dmitry Dmitrievich Genkin Treatment of diseases associated with protein misfolding by nervous system expression of an enzyme which has a deoxyribonuclease (dnase) activity
AU2020346914A1 (en) * 2019-09-13 2022-04-21 Lacerta Therapeutics, Inc Compositions and methods for treatment of Friedreich's Ataxia
BR112022006530A2 (pt) 2019-10-17 2022-07-05 Stridebio Inc Vetores virais adenoassociados para o tratamento da doença de niemann-pick tipo c
US20230211012A1 (en) * 2019-12-19 2023-07-06 The Trustees Of The University Of Pennsylvania Compositions for treating friedreich’s ataxia
CN113755524B (zh) * 2020-06-02 2023-11-03 舒泰神（北京）生物制药股份有限公司 用于治疗脊髓性肌萎缩的腺相关病毒载体及其用途
EP4188404A1 (en) 2020-07-29 2023-06-07 The Board Of Regents Of The University Of Texas System Transgene cassettes, aav vectors, and aav viral vectors for expression of human codon-optimized cstb
AU2021375404A1 (en) 2020-11-03 2023-06-08 Pfizer Inc. Methods for purification of aav vectors by anion exchange chromatography
IL303959A (en) 2020-12-23 2023-08-01 Pfizer Methods for purification of AAV vectors by affinity chromatography
EP4271420A1 (en) * 2021-01-04 2023-11-08 University Of Florida Research Foundation, Incorporated Methods and compositions for treatment of friedreich's ataxia
WO2022150772A1 (en) * 2021-01-11 2022-07-14 The Trustees Of The University Of Pennsylvania Compositions for treating friedreich's ataxia
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
WO2023114816A1 (en) 2021-12-14 2023-06-22 Neurogene, Inc. Recombinant optimized galc constructs and methods for treating galc-associated disorders
GB202201242D0 (en) 2022-01-31 2022-03-16 Univ Edinburgh Recombinant optimized mecp2 cassettes and methods for treating rett syndrome and related disorders
GB202206336D0 (en) 2022-04-29 2022-06-15 Univ Edinburgh Recombinant therapeutic FMR1 constructs and methods of treating fragile X syndrome and related disorders
WO2024003687A1 (en) 2022-06-28 2024-01-04 Pfizer Inc. Nucleic acids encoding acid alpha-glucosidase (gaa) and vectors for gene therapy
WO2024011109A2 (en) * 2022-07-06 2024-01-11 Adverum Biotechnologies, Inc. Compositions and methods for treatment of achromotopsia
CN117089514A (zh) * 2023-10-13 2023-11-21 思鹏生物科技(苏州)有限公司 提升hek293细胞系aav生产效率的细胞筛选驯化方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62144903A (ja) * 1985-12-19 1987-06-29 Nobuo Ikeda 木材への処理液注入方法
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US6204059B1 (en) 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
JP4108746B2 (ja) 1995-06-07 2008-06-25 ユニバーシティ オブ ノース カロライナ アット チャペル ヒル ヘルパーウイルスを含まないａａｖ産生
AU723497C (en) 1996-09-06 2001-10-11 Trustees Of The University Of Pennsylvania, The Method for recombinant adeno-associated virus-directed gene therapy
US20030215422A1 (en) 1996-09-11 2003-11-20 John A. Chiorini Aav4 vector and uses thereof
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
ATE402254T1 (de) 1998-05-28 2008-08-15 Us Gov Health & Human Serv Aav5 vektoren und deren verwendung
JP4573437B2 (ja) 1998-11-05 2010-11-04 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア アデノ随伴ウイルス血清型１核酸配列、ベクターおよび同一物を含有する宿主細胞
WO2000028004A1 (en) 1998-11-10 2000-05-18 The University Of North Carolina At Chapel Hill Virus vectors and methods of making and administering the same
ES2256265T3 (es) 2000-06-01 2006-07-16 University Of North Carolina At Chapel Hill Vectores de parvovirus duplicados.
CA2399576A1 (en) 2000-12-07 2002-06-13 Universite De Nantes Inducible highly productive raav packaging cell-lines
JP5054975B2 (ja) 2003-09-30 2012-10-24 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア アデノ随伴ウイルス（ａａｖ）の同源系統群、配列、それらを含有するベクターおよびそれらの用途
AU2005316476A1 (en) 2004-12-15 2006-06-22 University Of Florida Research Foundation, Inc. Chimeric vectors
EP2527367A1 (en) * 2007-08-20 2012-11-28 Glaxo Group Limited Production method
WO2010093784A2 (en) 2009-02-11 2010-08-19 The University Of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
WO2011084145A2 (en) * 2009-12-21 2011-07-14 Pharmathene, Inc. Recombinant butyrylcholinesterases and truncates thereof
CN102781952B (zh) * 2010-02-08 2015-09-02 宾夕法尼亚大学托管会 编码rantes的核酸分子、包含其的组合物以及其使用方法
EP2394667A1 (en) * 2010-06-10 2011-12-14 Laboratorios Del Dr. Esteve, S.A. Vectors and sequences for the treatment of diseases
US9593330B2 (en) * 2011-06-09 2017-03-14 Curna, Inc. Treatment of frataxin (FXN) related diseases by inhibition of natural antisense transcript to FXN
US9441206B2 (en) 2011-10-28 2016-09-13 The University Of North Carolina At Chapel Hill Cell line for production of adeno-associated virus
US9066966B2 (en) 2013-02-01 2015-06-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods and pharmaceutical compositions for the treatment of cardiomyopathy due to friedreich ataxia
EP3838297A1 (en) 2013-03-15 2021-06-23 The University of North Carolina at Chapel Hill Methods and compositions for dual glycan binding aav vectors
CN105612253A (zh) 2013-03-15 2016-05-25 费城儿童医院 含有填充者/填充物多核苷酸序列的载体及其制备方法
US11136557B2 (en) 2013-05-31 2021-10-05 The Regents Of The University Of California Adeno-associated virus variants and methods of use thereof
US11408899B2 (en) 2013-07-12 2022-08-09 The Children's Hospital Of Philadelphia AAV vector and assay for anti-AAV (adeno-associated virus) neutralizing antibodies
KR102380265B1 (ko) 2013-07-22 2022-03-29 더 칠드런스 호스피탈 오브 필라델피아 변종 ａａｖ 및 조성물, 세포, 기관 및 조직으로의 유전자 전이를 위한 방법 및 용도
CN106232618A (zh) 2013-10-11 2016-12-14 马萨诸塞眼科耳科诊所 预测祖先病毒序列的方法及其用途
GB201403684D0 (en) 2014-03-03 2014-04-16 King S College London Vector
BR112018007453A2 (pt) * 2015-11-05 2018-10-23 Bamboo Therapeutics Inc genes modificados de ataxia de friedreich e vetores para a terapia gênica

Also Published As

Publication number Publication date
PE20181156A1 (es) 2018-07-19
TW201920673A (zh) 2019-06-01
US20200384073A1 (en) 2020-12-10
WO2017077451A1 (en) 2017-05-11
JP2021019591A (ja) 2021-02-18
TWI654301B (zh) 2019-03-21
JP6767483B2 (ja) 2020-10-14
RU2018116076A3 (zh) 2020-08-21
KR20180077275A (ko) 2018-07-06
US20170128528A1 (en) 2017-05-11
RU2021102893A (ru) 2021-03-03
HK1250924A1 (zh) 2019-01-18
US10548947B2 (en) 2020-02-04
AU2020200976A1 (en) 2020-02-27
RU2743792C2 (ru) 2021-02-26
MX2018005084A (es) 2019-05-16
TWI743442B (zh) 2021-10-21
KR102200642B1 (ko) 2021-01-12
BR112018007453A2 (pt) 2018-10-23
AU2016347887A1 (en) 2018-04-19
RU2018116076A (ru) 2019-10-28
CN108348621A (zh) 2018-07-31
AU2020200976B2 (en) 2021-09-30
CO2018004564A2 (es) 2018-12-14
SG11201802408RA (en) 2018-05-30
KR20210005994A (ko) 2021-01-15
EP3370778A1 (en) 2018-09-12
AU2016347887B2 (en) 2019-11-14
CA2947584A1 (en) 2017-05-05
JP2018531609A (ja) 2018-11-01
PH12018500964A1 (en) 2018-11-12
TW201723179A (zh) 2017-07-01
IL259141A (en) 2018-06-28

Similar Documents

Publication Publication Date Title
HK1250924A1 (zh) 用於基因治療的經修飾的弗里德賴希共濟失調基因及載體
HK1258288A1 (zh) 核酸酶非依賴性靶向基因編輯平台及其用途
HK1257801A1 (zh) 用於基因治療的腺伴隨病毒載體的鞘內給藥
IL284577A (en) Garden healing
HK1257078A1 (zh) 優化的因子viii基因
HUE054768T2 (hu) AAV vektorok retina és CNS génterápiára
IL263009A (en) Optimal clni genes and expression cassettes and their use
PT3612237T (pt) Terapia genética
HK1257519A1 (zh) 用於 galgt2 基因治療的方法和物質
IL257500A (en) Altered cullin1 gene
GB201707212D0 (en) Gene therapy for ciliopathies
GB2572716B (en) Gene Therapy Vector System and Prodrug Genes
PL3638796T3 (pl) Wektory ekspresyjne zawierające zmodyfikowane geny
GB201701968D0 (en) Gene therapy
EP2968612A4 (en) MODIFIED SOLUBLE VEGF RECEPTOR 1 GENES AND VECTORS FOR GENE THERAPY
GB201513151D0 (en) Functional gene replacement therapy
IL263085A (en) Garden healing
GB201704634D0 (en) Gene therapy
GB201616821D0 (en) Gene therapy
GB201612105D0 (en) Gene therapy
GB201612104D0 (en) Gene therapy
SG10201912076UA (en) Gene therapy composition